Kaplan Fox & Kilsheimer LLP announces that class action lawsuits have been filed against Hims & Hers Health, Inc. (“Hims & Hers” o ...

Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HIMS & HERS HEALTH, INC. (HIMS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 25, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Our writer reveals what he thinks is the most exciting from the four investments he made in his Stocks and Shares ISA last ...

Investing.com -- AI-related stocks topped trading activity on Robinhood U.K. in June, led by Nvidia (NASDAQ: NVDA ), ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Hims & Hers' high valuation is no longer justified amid mounting execution and revenue risks. Click here to read why I ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

California lawmakers introduced bills to increase doctors' menopause training. ( NPR) The majority of people in the U.S. who ...

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.